Drug
Fks518
Fks518: highest development phase Phase 3, developed by Fresenius Kabi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Fresenius Kabi
Trials
| Drug | Phase | Indication |
|---|---|---|
| FKS518 NCT04934072 | Phase 3 | Postmenopausal Osteoporosis |
Latest
No recent events.
Follow Fks518 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.